MODERATOR(S)
Malolan Rajagopalan, MD, MBA - Mount Carmel Health System
session DESCRIPTION
The management of non-small cell lung cancer (NSCLC) has rapidly evolved with the integration of immunotherapy across early-stage, locally advanced and metastatic disease, creating new challenges and opportunities for radiation oncologists. This session will focus on multidisciplinary, decision-driven approaches to contemporary NSCLC care, emphasizing areas in which evolving systemic therapy and staging paradigms directly influence radiation treatment strategy. - The first topic will address the optimal management of stage III NSCLC in the chemo-immunotherapy era, with emphasis on patient selection, the role of radiation therapy in the post-neoadjuvant setting, and target delineation following neoadjuvant therapy. - The second topic will explore the role of mediastinal staging in both early-stage and advanced NSCLC, highlighting the indications, techniques and diagnostic yield of endobronchial ultrasound (EBUS) in the upfront and post-neoadjuvant setting. The impact of mediastinal staging results on radiation treatment planning will be discussed. - The third topic will review the evidence supporting stereotactic body radiation therapy (SBRT) for oligometastatic and oligoprogressive NSCLC, focusing on patient selection, timing of SBRT relative to systemic therapy, and practical considerations for integrating SBRT with immune checkpoint inhibitors. In summary, this session will provide practical guidance to help radiation oncologists navigate complex clinical decision making in the modern NSCLC treatment landscape.
learning objectives
- Analyze patient- and disease-specific factors to determine optimal management strategies for stage III NSCLC in the chemo-immunotherapy era, including selection of patients for definitive chemoradiation versus neoadjuvant therapy.
- Identify appropriate indications for mediastinal staging with endobronchial ultrasound (EBUS) in both early-stage and advanced NSCLC.
- Evaluate patients with oligometastatic or oligoprogressive NSCLC to determine when SBRT should be integrated with systemic therapy.
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
10:45am - 10:47am ETSpeaker: Malolan Rajagopalan, MD, MBA - Mount Carmel Health System, Grove City
-
10:47am - 11:07am ETSpeaker: Pranshu Mohindra, MD, MMM - University Hospitals Seidman Cancer Center, Cleveland, OH, Cleveland
-
11:07am - 11:27am ETSpeaker: Jason Beattie, MD - Beth Israel Deaconess Medical Center, Framingham
-
11:27am - 11:47am ETSpeaker: Benjamin Lok, MD, BS - Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto
-
11:47am - 12:00pm ETSpeaker: Malolan Rajagopalan, MD, MBA - Mount Carmel Health System, Grove City